Smith & Nephew PLC (SNNUF)
SNNUF is quoted over the counter, not listed on an exchange. Smith & Nephew PLC files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | SNNUF, quoted over the counter |
| SEC CIK | 0000845982 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Orthopedic, Prosthetic & Surgical Appliances & Supplies |
| Business address | Watford, Hertfordshire |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In 2022, the Group recognised an impairment charge of $ 109 m on its investment in Bioventus due to a significant decline in share price and the company has disclosed a substantial doubt about their ability to continue as a going concern." | 20-F 2026-03-16 |
| Cash and burn | $557.0M cash; operating cash flow $321.3M a quarter. | Report 2025-12-31 |
| Shares outstanding | 438,862,423 (2025-12-31); 438,852,093 a year earlier; 438,824,793 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns | Latest 2026-09-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-10-05 |
| Auditor | Deloitte LLP, London, United Kingdom | PCAOB Form AP 2026-04-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $6.2B | $625.0M | $1.3B | $557.0M | $3.1B | $6.2B | 20-F 2026-03-16 |
| FY 2024 2024-12-31 | $5.8B | $412.0M | $987.0M | $619.0M | $3.1B | $5.8B | 20-F 2026-03-16 |
| FY 2023 2023-12-31 | $5.5B | $263.0M | $608.0M | $302.0M | $2.9B | $5.5B | 20-F 2026-03-16 |
| FY 2022 2022-12-31 | $5.2B | $223.0M | $468.0M | $350.0M | $2.7B | $5.2B | 20-F 2025-03-10 |
| FY 2021 2021-12-31 | $5.2B | $524.0M | $877.0M | $1.3B | $3.1B | $5.2B | 20-F 2024-03-11 |
| FY 2020 2020-12-31 | $4.6B | $448.0M | $935.0M | $1.8B | $3.5B | $4.6B | 20-F 2023-03-06 |
| FY 2019 2019-12-31 | $5.1B | $600.0M | $1.2B | $257.0M | $1.9B | $5.1B | 20-F 2022-03-07 |
| FY 2018 2018-12-31 | $4.9B | $663.0M | $931.0M | $333.0M | $1.5B | $4.9B | 20-F 2021-03-01 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-10 |
| Latest annual report | 20-F | 2026-03-16 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier